Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to discovering, developing, and commercializing oral antiviral therapies aimed at treating severe viral diseases. Founded in 2012, Atea focuses on addressing unmet medical needs, particularly in serious viral infections caused by single-stranded RNA viruses.
The company's leading product candidate is AT-527 (bemnifosbuvir), an antiviral agent developed for treating COVID-19, caused by the SARS-CoV-2 virus. Currently, AT-527 is undergoing Phase 3 clinical trials. Additionally, the combination of bemnifosbuvir and ruzasvir, an oral NS5A inhibitor, is being developed for treating Hepatitis C Virus (HCV) and has shown promising results in Phase 2 trials. This combination therapy aims to provide a highly potent pan-genotypic antiviral treatment with a short treatment duration and fewer contraindications, particularly beneficial for HCV patients.
Beyond COVID-19 and HCV, Atea is also advancing other antiviral therapies in its pipeline, including AT-787 for Hepatitis C (under Phase 2 clinical trial), AT-752 for Dengue (under Phase 2 trial), and other candidates like AT-889 and AT-934 for Respiratory Syncytial Virus (currently under clinical trials).
Recent achievements include positive initial data from a Phase 2 study of bemnifosbuvir and ruzasvir for HCV, showing a 97% sustained virologic response rate at 12 weeks post-treatment. Furthermore, Atea has completed enrollment for the Phase 3 SUNRISE-3 trial for treating high-risk COVID-19 patients, with results expected in the second half of 2024.
Financially, Atea reported a solid cash position of $578.1 million as of December 31, 2023, enabling them to continue advancing their clinical programs. Collaborations and strategic partnerships play a crucial role in Atea’s progress, helping to broaden its scope and enhance its therapeutic offerings.
Investors and stakeholders can stay informed about Atea’s developments through their regular updates, financial reports, and participation in industry conferences. For more information, visit their official website at www.ateapharma.com.
Atea Pharmaceuticals (NASDAQ: AVIR) reported Q2 2024 financial results and provided a business update. Key highlights include:
- Full enrollment achieved in global Phase 2 HCV study; SVR12 results expected Q4 2024
- COVID-19 Phase 3 SUNRISE-3 trial results expected H2 2024
- Cash position of $502.2 million as of June 30, 2024
- Q2 2024 R&D expenses increased to $34.7 million from $22.1 million in Q2 2023
- Net loss of $40.5 million for Q2 2024 compared to $28.2 million in Q2 2023
The company completed enrollment in both the HCV Phase 2 study and COVID-19 Phase 3 SUNRISE-3 study. Positive HCV data presented at EASL showed 97% SVR12 rate in lead-in cohort. Atea selected a fixed-dose combination tablet for HCV Phase 3 program.
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics for serious viral diseases, has announced its upcoming second quarter 2024 financial results conference call. The event is scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET.
Participants can join the live audio webcast through the Investor Relations section of Atea's website. For those joining via telephone, pre-registration is required. The company will provide a business update along with the financial results for the quarter ended June 30, 2024. An archive of the webcast will be available on Atea's website for at least 90 days following the event.
Atea Pharmaceuticals announced positive initial results from their Phase 2 study combining bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). The lead-in cohort of 60 patients showed a 97% sustained virologic response rate at 12 weeks post-treatment (SVR12) following an 8-week regimen. This combination therapy displayed high antiviral potency, short treatment duration, low risk of drug interaction, and a high barrier to resistance.
Additionally, a 100% SVR12 rate was observed in patients with the difficult-to-treat genotype 3. The study reported no severe drug-related adverse events or treatment discontinuations. Atea aims to enroll up to 220 more subjects, including those with compensated cirrhosis. These promising results were shared at the EASL Congress in Milan, Italy, from June 5-8, 2024, highlighting the potential best-in-class profile of the drug combination.
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical firm focused on developing oral antiviral treatments for severe viral diseases, announced that CEO and Founder Jean-Pierre Sommadossi, PhD, will present a business update at the Jefferies Healthcare Conference. The presentation is scheduled for June 5, 2024, at 10:30 a.m. ET in New York. Both a live and archived webcast of the presentation will be accessible on Atea's website.
Atea Pharmaceuticals will present new data on the combination of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV) at the EASL Congress 2024. The presentations will showcase antiviral efficacy, including SVR12 data from the ongoing Phase 2 HCV trial's lead-in cohort. Preclinical data highlight bemnifosbuvir's high resistance barrier and pharmacokinetics, and ruzasvir's low risk of drug-drug interactions. The full dataset will be available on the EASL Congress website on June 5, 2024. HCV remains a significant health issue in the U.S., with over 2 million chronic cases and annual diagnoses outpacing cure rates.
Atea Pharmaceuticals reported Q1 2024 financial results, highlighting key developments in their COVID-19 and HCV treatment trials. The company completed enrollment in the global Phase 3 SUNRISE-3 trial for bemnifosbuvir in high-risk COVID-19 patients, with results expected in H2 2024. Additionally, they are progressing in their Phase 2 trial for HCV treatment with bemnifosbuvir and ruzasvir, also expecting results in H2 2024. Financially, Atea reported a net loss of $63.2 million, up from $35.5 million YoY, primarily due to increased R&D expenses. Cash and equivalents stood at $541.5 million, down from $578.1 million at the end of 2023.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) will host a conference call on May 14, 2024, to report financial results for the first quarter ended March 31, 2024, and provide a business update. Participants can access the live webcast on the company's Investor Relations website. Telephone registration is required for participation.
Atea Pharmaceuticals, Inc. announced the Phase 1 data presentation at ESCMID Global 2024, highlighting the favorable safety profile of bemnifosbuvir, an oral nucleotide polymerase inhibitor. The results show no cardiotoxicity in healthy participants, supporting the drug's safety profile. Atea aims to address the unmet need for COVID-19 and HCV treatments. Phase 3 SUNRISE-3 trial for COVID-19 and Phase 2 trial for HCV are upcoming in 2024.
FAQ
What is the current stock price of Atea Pharmaceuticals (AVIR)?
What is the market cap of Atea Pharmaceuticals (AVIR)?
What is Atea Pharmaceuticals, Inc.?
What are the main products developed by Atea Pharmaceuticals?
What is the status of the AT-527 (bemnifosbuvir) clinical trials?
What recent achievements has Atea Pharmaceuticals made?
Where is Atea Pharmaceuticals headquartered?
How does Atea Pharmaceuticals plan to address unmet medical needs?
What is the financial condition of Atea Pharmaceuticals?
How can I get more information about Atea Pharmaceuticals?
What are the expected upcoming events for Atea Pharmaceuticals?
Who should be interested in Atea Pharmaceuticals’ updates?
